SOMI Crashes 17% From $1.90 Peak, Eyes Breakdown Below $1 as Traders Exit
Somnia’s SOMI token is under pressure after a 17% drop from its peak, with weakening momentum and falling open interest signaling more downside risk.
Somnia’s native token, SOMI, has drawn strong market attention since the recent launch of its Ethereum-compatible mainnet. The excitement fueled a rapid rally, propelling the token to an all-time high of $1.90 by Sunday.
However, the surge also triggered a wave of profit-taking, which is now weighing heavily on its price and raising the risk of deeper declines.
Profit-Taking Hits SOMI After Launch Rally
Readings from the SOMI/USD four-hour chart show the token’s Money Flow Index (MFI) declining, reflecting the uptick in selloffs.
For token TA and market updates: Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter
SOMI MFI. Source:
TradingView
The MFI, which measures both price and trading volume to assess buying and selling pressure, climbs when capital flows into an asset and falls when outflows dominate. Therefore, SOMI’s current MFI setup highlights that buyers are losing ground, and sellers are beginning to dictate market direction.
Moreover, the token’s downward trend has pushed its price toward the 20-day exponential moving average (EMA), confirming the dip in buy-side pressure.
SOMI 20-Day EMA. Source:
TradingView
The 20-day EMA measures an asset’s average price over the past 20 trading days, giving more weight to recent prices.
When prices consistently trade above this line, it reflects sustained buying momentum and confidence in further upside. However, a decisive breach below the EMA typically signals a shift in sentiment, as buyers lose control and bears begin to dominate.
For SOMI, slipping under this level would mark a transition from its initial post-launch bullish euphoria to a bearish phase, opening the door to deeper losses.
Furthermore, sentiment among the token’s derivatives traders has also turned bearish, reflected by its plunging futures open interest. At press time, it was $84.90 million, falling by 28% in the past 24 hours.
SOMI Futures Open Interest. Source:
Coinglass
Open interest represents the total number of outstanding futures contracts that have not yet been settled, and it is often used to gauge the strength behind market trends.
Rising open interest signals that new money is flowing into the market, reinforcing the prevailing price direction, while a decline indicates that traders are closing positions and stepping away.
Therefore, SOMI’s falling futures open interest highlights fading appetite and a loss of confidence in its sustained upside.
SOMI Risks $0.91 if Bulls Lose $1 Support
A close below the 20-day EMA would open the door to a steeper decline to $1.10. If SOMI bulls fail to defend this level, a dip below the $1 price mark could cause the altcoin to trade at $0.91.
SOMI Price Analysis. Source:
TradingView
However, if new demand enters the market, SOMI could regain strength and resume its uptrend toward $1.56.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
